Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRN – Research Report), Humana (HUM – Research Report) and Moderna (MRNA – Research Report). BioMarin Pharmaceutical (BMRN) Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical yesterday and set a price target of $100.00. The company's shares closed last Tuesday at $86.29. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-humana-hum-and-moderna-mrna?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Moderna Charts.